Prof dr. Hugo ten Cate

Steering Committee
Chair and Local Organizing Committee
h.tencate@maastrichtuniversity.nl
Maastricht, The Netherlands

Description

Prof. Hugo ten Cate graduated in Medicine at the University of Amsterdam in 1987. The title of his PhD thesis was 'Clinical and experimental studies with a low molecular weight heparinoid'. Hugo had his post-doctoral training at the laboratory of Prof. Robert Rosenberg and Dr Kenneth Bauer at the Beth Israel Hospital and Harvard Medical School Boston on mechanisms of inflammation associated coagulation activity (1988-1990). He completed his internal medicine training in 1996 and became a general internist in conjunction with research at Academic Medical Center (laboratory of Experimental Internal medicine, Prof. Pieter Reitsma). He received a Clinical Established Investigator grant from the Dutch Heart Foundation in 1998.

In 2002, Hugo ten Cate was appointed Professor of Clinical Thrombosis and Haemostasis at CARIM. In addition, Prof. ten Cate was appointed adjunct professor at the Center for Thrombosis and Haemostasis (CTH) at Gutenberg University Medical Center, Mainz, Germany in 2017

Since the transfer to CARIM in 2002 his research focus shifted from coagulation-inflammation research in sepsis models, to the broader field of cardiovascular (CV) disease (atherothrombosis and 'thrombo-inflammation'). A specific focus of current research is the pleiotropic actions of coagulation proteases in atherosclerosis, atherothrombosis and ischemia reperfusion injury. Clinical research is aimed at chronic thrombotic disease including peripheral artery disease, high risk patients with coronary disease on antithrombotic medication and, together with Dr Arina ten Cate-Hoek, on venous thrombosis and post thrombotic syndrome (PTS). He is workpackage leader in CVON consortia RACE-5 (coagulation and its impact on atrial fibrillation) and CONTRAST (acute ischemic stroke) and involved in the ITN consortia TAPAS and TICARDIO. His group has an ongoing target finding programme with Bayer (steered from CARIM by Dr Henri Spronk and Prof. Hugo ten Cate) as well as with 2M (on POC development).